Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 56.15 -1.16 (-2.02%) Streaming Delayed Price Updated: 2:34 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 3 4 5 6 7 8 9 ... 30 31 Next > Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year February 01, 2024 After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February. Via Benzinga MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session February 01, 2024 U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday. Via Benzinga Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation January 26, 2024 FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients. Via Benzinga Exposures Product Safety Analyzing NASDAQ:SNY's Dividend Potential. January 24, 2024 Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY). Via Chartmill Why NASDAQ:SNY is a Top Pick for Dividend Investors. January 02, 2024 Analyzing SANOFI-ADR (NASDAQ:SNY)'s Dividend Potential. Via Chartmill Looking Into Sanofi's Recent Short Interest December 21, 2023 Via Benzinga Earnings Scheduled For February 1, 2024 February 01, 2024 Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... Via Benzinga Sanofi's Earnings Outlook January 31, 2024 Via Benzinga Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? January 29, 2024 An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) January 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx January 23, 2024 The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency. Via Investor's Business Daily French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B January 23, 2024 Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected... Via Benzinga Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project January 23, 2024 Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO. Via Benzinga Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades January 22, 2024 HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape. Via Benzinga Time to buy these 3 healthcare companies that raised revenue guidance? January 16, 2024 The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. Via MarketBeat Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space January 12, 2024 The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. Via Investor's Business Daily Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation January 10, 2024 French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger... Via Benzinga Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering January 05, 2024 Shares soared and then tumbled Friday after the company offered $275 million in public shares. Via Investor's Business Daily More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 January 04, 2024 More than 140 brands of drugs are going to see their prices hiked heading into the new year Via Talk Markets China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants January 02, 2024 Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD Via Benzinga Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January December 29, 2023 Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on... Via Benzinga NASDAQ:SNY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. December 28, 2023 SANOFI-ADR (NASDAQ:SNY): good value for what you're paying. Via Chartmill Why First Wave BioPharma Shares Are Skyrocketing Today December 27, 2023 First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Niclosamide program for the treatment of Via Benzinga Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today? December 21, 2023 MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) compan Via Benzinga European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data December 21, 2023 Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr Via Benzinga First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline December 18, 2023 First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for... Via Benzinga 7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar December 17, 2023 While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. Via InvestorPlace It's Almost 2024: 3 Top Stocks to Buy Before the New Year December 17, 2023 You can pick these players up for a great price right now. Via The Motley Fool French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment December 15, 2023 Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium Via Benzinga 3 Stocks to Buy Before 2024 That Can Set You Up For Life December 14, 2023 These stocks are still relatively cheap, but don't expect them to stay that way for long. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 ... 30 31 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.